Ref. Ares(2016)4049973 - 02/08/2016
Ref. Ares(2016)7049618 - 19/12/2016
From:
(BEUC) <
@beuc.eu>
Sent:
29 July 2016 14:52
To:
(SANTE)
Cc:
(BEUC);
(SANTE);
(SANTE)
Subject:
RE: Meeting with BEUC re. the development of criteria for identifying
endocrine disruptors
Attachments:
beuc-x-2016-077_BEUC_regulation_of_EDCs.pdf
Dear
,
I hope this message finds you well.
As a follow-up to the June 30 stakeholder meeting on criteria to identify endocrine
disruptors, BEUC has published a position paper in which we express our deep concerns in
the Commission’s proposal and call on the EU to better protect consumers. Please find
attached a copy of the paper for your information.
We hope the Commission will take our concerns into account. We look forward to have the
opportunity to discuss our concerns with you in more detail after the summer break.
With kind regards
Rue d'Arlon 80
B-1040 Brussels
Tel. +32(0)2
Mob. +32(
@beuc.eu
www.beuc.eu
Consult our entry in the EC register for interest representatives
Think before you print
From:
@ec.europa.eu [mailto:
@ec.europa.eu]
Sent: 26 May 2016 12:00
To:
(BEUC)
@beuc.eu>
Cc:
(BEUC) <
@beuc.eu>;
@ec.europa.eu;
@ec.europa.eu
Subject: RE: Meeting with BEUC re. the development of criteria for identifying endocrine disruptors
Dear
Let me first apologize for my very late reply to your e-mail and for the fact
that you had to remind me about my outstanding response. Due to
extremely heavy workload over the last weeks and in the coming weeks I
was and will not be in a position to meet you before mid-June. Can I
suggest that you get in contact with my assistant,
(in copy),
to set up a date in the second half of June.
Kind regards,
From:
(BEUC) [mailto
@beuc.eu]
Sent: Monday, April 11, 2016 3:57 PM
To:
(SANTE)
Cc:
(BEUC)
Subject: Meeting with BEUC re. the development of criteria for identifying endocrine disruptors
Dear
I write concerning the European Commission’s work to define criteria for identifying
chemicals with endocrine disrupting properties. BEUC, The European Consumer
Organisation, is concerned that the delay in setting criteria for endocrine disruptors
may create unnecessary health risks for consumers.
As head of the unit leading the Commission’s work related to the criteria, I was
hoping you might be available in the near future to meet with me and my colleague,
, to discuss our concerns. We would also be very interested in learning
more about the current status regarding the criteria as well as how the Commission
plans to proceed once a set of final criteria have been proposed and adopted.
I look forward to your reply.
With kind regards,
Rue d'Arlon 80
B-1040 Brussels
Tel. +32(0)2
Mob. +
@beuc.eu
www.beuc.eu
Consult our entry in the EC register for interest representatives
Think before you print